Subclonal response heterogeneity to define cancer organoid therapeutic sensitivity

Area of Science:

• Oncology
• Cancer Biology
• Genomics

Background:

• Tumor heterogeneity poses a challenge for precision medicine, limiting treatment efficacy.
• Current sequencing technologies struggle to detect rare cancer cell populations.
• Patient-derived organotypic cultures accurately model primary tumor molecular features.

Purpose of the Study:

• To demonstrate the advantage of evaluating individual patient-derived cancer organoid (PCO) heterogeneity for predicting clinical response.
• To explore the potential of organoid subcultures in identifying subclonal populations with varied treatment responses.
• To investigate dose-escalation effects of targeted therapy on PCOs and pathway expression.

Main Methods:

• Utilized patient-derived cancer organoids (PCOs) to model tumor heterogeneity.
• Performed subculture analysis to assess clonal diversity and treatment response.
• Conducted dose-escalation studies with anti-EGFR therapy on PCOs.
• Analyzed pathway expression changes in response to targeted therapy.

Main Results:

• Individual PCO heterogeneity evaluation significantly enhances prediction of clinical response.
• Organoid subcultures identified subclonal populations exhibiting altered treatment responses.
• Dose escalation of anti-EGFR therapy revealed divergent pathway expression compared to pretreatment cultures.
• PCOs identified molecular heterogeneity not detectable by bulk tumor sequencing.

Conclusions:

• Population-based organoid response assessments are vital for precision oncology.
• Patient-derived cancer organoids (PCOs) are powerful tools for uncovering molecular heterogeneity.
• PCO heterogeneity analysis is crucial for understanding and overcoming therapeutic resistance mechanisms.